TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

TG Therapeutics, Inc. presented updated clinical data at the MSToronto2026 meeting, showcasing seven-year follow-up results from the ULTIMATE I & II trials and findings from the Phase 1 subcutaneous BRIUMVI study. The company also shared data from the Phase 3 ENHANCE trial and an update from the ENABLE real-world study, focusing on the anti-CD20 monoclonal antibody, BRIUMVI, for treating relapsing forms of multiple sclerosis.